Lercanidipine/enalapril fixed combination - Recordati

Drug Profile

Lercanidipine/enalapril fixed combination - Recordati

Alternative Names: Atover; Carmen ACE; Coripren; Lercaprel; Lercapress; Zan-Extra; Zaneril; Zanextra; Zanipress; Zanipril; Zanitek

Latest Information Update: 19 Aug 2016

Price : $50

At a glance

  • Originator Recordati
  • Class Antihypertensives; Dihydropyridines; Dipeptides; Small molecules
  • Mechanism of Action ACE inhibitors; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension
  • Registered Essential hypertension

Most Recent Events

  • 05 Aug 2016 Meda has been acquired by Mylan
  • 30 Mar 2015 The product is approved for Hypertension in Iceland
  • 10 Oct 2014 Rottapharm Madaus has been acquired by Meda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top